EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeitOpen Access · CC BY 4.0

Dose‐dependent effect of megestrol acetate supplementation in cancer patients with anorexia–cachexia syndrome: A meta‐analysis

Dosisabhängiger Effekt einer Megestrolacetat-Supplementierung bei Krebspatient:innen mit Anorexie-Cachexie-Syndrom: Metaanalyse

Sepide Talebi, Sheida Zeraattalab-Motlagh, Maryam Barkhordar, Mohammad Vaezi, Seyed Mojtaba Ghoreishy, Abed Ghavami, Yasaman Hosseini, Nikolaj Travica, Hamed Mohammadi

Journal of Cachexia, Sarcopenia and Muscle · 2024-08 · 15 (4) · 1254-1263

DOI: 10.1002/jcsm.13500 ↗

Auf einen Blick

13 RCTs zeigen für Megestrolacetat bei Krebs-assoziierter Anorexie/Cachexie keinen klaren Effekt auf die Gewichtszunahme. In der Dosis-Wirkungs-Analyse stieg die Gewichtszunahme nur gering.

Fragestellung

Welche dosisabhängigen Effekte hat Megestrolacetat bei Patient:innen mit Krebs-assoziierter Anorexie/Cachexie auf Gewicht, Appetit, Müdigkeit und Lebensqualität?

Methode

Metaanalyse randomisierter kontrollierter Studien; Suche in PubMed, Scopus und ISI Web of Science bis Juni 2023; random-effects, GRADE.

Ergebnisse

13 Studien mit 1229 Teilnehmenden. Höchstdosis vs. Niedrigstdosis: Gewicht MD 0,64 kg (95 %-KI −0,11 bis 1,38), I2=69,1 %, GRADE sehr niedrig. Pro 200 mg/Tag: MD 0,44 (95 %-KI 0,13 bis 0,74).

Einschränkungen

Sehr niedrige Evidenz; hohe Heterogenität bei der Dosis-Wirkungs-Analyse (I2=97,1 %).

Schlussfolgerung der Autor:innen

Mit sehr niedriger Evidenz führt Megestrolacetat vermutlich nicht zu einer signifikanten Gewichtszunahme oder klaren Effekten auf weitere Outcomes.

Kernaussagen

  • Gewicht: kein signifikanter Effekt in Höchstdosis-vs.-Niedrigstdosis-Analyse
  • Pro 200 mg/Tag nur kleiner Anstieg der Gewichtszunahme
  • Appetit und Müdigkeit ohne signifikanten Effekt; QoL verbessert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 20.06.2024. Verfasst von Sepide Talebi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Cachexia, Megestrol Acetate, Neoplasms, Anorexia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Haematology-Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran University of Medical Sciences and Health Services.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is inconsistent evidence relating to the effects of megestrol acetate (MA) supplementation on cancer patients suffering from anorexia–cachexia syndrome. This review aimed to examine the dose–response effect of MA supplementation in patients with cancer‐associated anorexia/cachexia. Relevant keywords were searched in PubMed, Scopus and ISI Web of Science from inception to June 2023 for randomized controlled trials (RCTs) examining the effect of MA on pathologies in patients with cancer‐associated cachexia. Our primary outcomes were changes in body weight and appetite. However, fatigue and quality of life were secondary outcomes. The mean difference (MD) and 95% confidence interval (95% CI) were estimated using the random‐effects method. Thirteen trials comprising 1229 participants (mean age 60 years) were identified. The results of our highest versus lowest analysis revealed that MA supplementation was not associated with any increase in body weight (MD: 0.64 kg, 95% CI [−0.11, 1.38], P = 0.093, I 2 = 69.1%; GRADE = very low certainty). Twelve trials, including 14 effect sizes derived from 1369 patients (intervention = 689, control = 680), provided data on the effect of MA on body weight. Subgroup analyses showed a significant increase in body weight following short‐term intervention (≤8 weeks) and a combination of radiation/chemotherapy as concurrent treatment. A linear dose–response meta‐analysis indicated that each 200 mg/day increment in MA consumption had a significant increase in weight gain (MD: 0.44; 95% CI [0.13, 0.74], P = 0.005; I 2 = 97.1%); however, the magnitude of the effect was small. MA administration significantly affected the quality of life based on pooled effect sizes (MD: 1.15, 95% CI [0.76, 1.54], P < 0.001, I 2 = 0%; n = 2 RCTs including 176 patients; GRADE = very low certainty). However, no significant effect of MA supplementation was observed on appetite (MD: 0.29, 95% CI [−0.05, 0.64], P = 0.096, I 2 = 18.3%; n = 3 RCTs including 163 patients; GRADE = very low certainty) and fatigue (MD: 0.14, 95% CI [−0.09, 0.36], P = 0.236, I 2 = 0%; n = 2 RCTs including 300 patients; GRADE = very low certainty). With very low certainty of the evidence, MA supplementation may not lead to a significantly increased weight gain and other outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CachexiaMegestrol AcetateNeoplasmsAnorexiaDietary SupplementsHumansQuality of LifeDose-Response Relationship, DrugBody Weight

Stichwörter der Autor:innen

anorexiaappetitecachexiacancermegestrol acetate

Substanzen

Megestrol Acetate

Autor:innen und Institutionen

  • Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Health and Human Performance, University of Houston, Houston, TX, USA.
  • Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.
  • Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Förderung

  • Haematology-Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences
  • Tehran University of Medical Sciences and Health Services

Zitieren

APA

Talebi, S., Zeraattalab-Motlagh, S., Barkhordar, M., Vaezi, M., Ghoreishy, S. M., Ghavami, A., Hosseini, Y., Travica, N., & Mohammadi, H. (2024). Dose‐dependent effect of megestrol acetate supplementation in cancer patients with anorexia–cachexia syndrome: A meta‐analysis. Journal of Cachexia, Sarcopenia and Muscle, 15(4), 1254-1263. https://doi.org/10.1002/jcsm.13500

Vancouver

Talebi S, Zeraattalab-Motlagh S, Barkhordar M, Vaezi M, Ghoreishy SM, Ghavami A, et al. Dose‐dependent effect of megestrol acetate supplementation in cancer patients with anorexia–cachexia syndrome: A meta‐analysis. Journal of Cachexia, Sarcopenia and Muscle. 2024;15(4):1254-1263. doi:10.1002/jcsm.13500

BibTeX
@article{Talebi2024,
  author = {Talebi, Sepide and Zeraattalab-Motlagh, Sheida and Barkhordar, Maryam and Vaezi, Mohammad and Ghoreishy, Seyed Mojtaba and Ghavami, Abed and Hosseini, Yasaman and Travica, Nikolaj and Mohammadi, Hamed},
  title = {Dose‐dependent effect of megestrol acetate supplementation in cancer patients with anorexia–cachexia syndrome: A meta‐analysis},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2024},
  volume = {15},
  number = {4},
  pages = {1254--1263},
  doi = {10.1002/jcsm.13500}
}
Kostenlos starten →